Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Bill Steinman
Contributing Editor

Inside view: What do corrupt organizations look like?

The concept of corporate culture — generally defined as “the way we do things around here” — isn’t a rigid paper process. It’s hard to measure, which explains why corporate culture has been largely neglected by regulators and the anti-corruption-consulting industry.… Continue Reading

GSK has ‘zero tolerance’ for graft: Matching company policy with corporate action (Part 1)

A recent post on FCPA Blog about various ongoing investigations into alleged corrupt practices at GlaxoSmithKline in at least five countries included a quote attributed to GSK that the company has “zero tolerance for unethical or illegal behavior.”
I found this an extraordinary position for GSK to adopt, given the incidents of alleged corruption that may have been around for over a decade.
Continue Reading